MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights...

Area of Science:

• Oncology
• Genetics
• Biomarker Discovery

Background:

• Chronic lymphocytic leukemia (CLL) management often involves a "watch and wait" strategy, delaying treatment until disease progression.
• Accurate prediction of treatment requirement is crucial for optimizing patient management and therapeutic strategies in CLL.
• Existing prognostic models utilize established biomarkers but may benefit from novel predictive factors.

Purpose of the Study:

• To investigate the predictive role of microRNAs (miRNAs) in determining the time to first treatment (TTFT) for CLL patients.
• To assess whether integrating miRNA expression data can enhance existing prognostic models for CLL.
• To explore the biological pathways and gene correlations associated with predictive miRNAs in CLL.

Main Methods:

• Prospective O-CLL1 study involving 224 CLL patients.
• Analysis of 513 miRNAs for association with TTFT using univariable and multivariable models.
• Integration of significant miRNAs into a basic prognostic model with established variables (Rai stage, beta-2-microglobulin, IGVH status, del11q, del17p, NOTCH1 mutations).
• In silico analyses and miRNA-mRNA correlation studies to explore regulatory functions and biological context.

Main Results:

• Six established variables predicted TTFT with a C-index of 75%.
• 16 out of 513 miRNAs showed a significant independent association with TTFT.
• Integrating these miRNAs into the model improved predictive accuracy (C-index 81.1%) and explained variance (63.3%), significantly enhancing discrimination and reclassification.
• In silico analyses suggested regulatory roles in therapeutic response pathways; miRNA-mRNA correlations identified links with AI-selected genes relevant to TTFT.

Conclusions:

• Specific miRNAs are promising predictors of TTFT in CLL, offering potential for improved risk stratification.
• The integration of miRNA biomarkers can significantly refine prognostic models, aiding clinical decision-making for CLL treatment.
• Further validation and functional studies are necessary to translate these findings into clinical utility.